No. 1 Story

ACCC clears Optus to scrap HFC network and use NBN instead

The ACCC has cleared, provisionally, the proposed deal between Optus and NBN Co under which Optus is to be paid around $800m to shut down its HFC network and transfer customers onto the NBN. read more

Dysport approved by FDA for wrinkle treatment

Science - Health



The WebMD article FDA Approves New Wrinkle Treatment states that the manufacturer of Dysport, Ipsen Biopharm Ltd, indicates that “One clinical trial showed 93%-95% of participants noticed an improvement in the appearance of forehead wrinkles within seven days after treatment, and multiple treatments produced effects that lasted for more than 13 months.”

The study used about 2,900 subjects at eighty different locations.

It is reported that the most common adverse side effects of Dysport are headeache, pain and skin reaction at the injection site, throat and nose irritation, upper respiratory tract infection, sinus inflammation, nausea, and eyelid swelling or drooping.

The FDA also approved Dysport as a way to treat adult cervical dystonia (also called spasmodic torticillis), which is a condition that causes severe and abnormal positioning of the head, along with neck pain.

It is caused when the neck muscles that control the positioning of the head  are adversely affected. They cause the head to twist and turn to one side, or pull forward or backward.

Dysport will be available for cosmetic use (for forehead wrinkles and frown lines) sometime around June or July 2009. It will become available for medical use (to treat cervical dystonia) in the last half of 2009.

For more information on the adverse reactions found with these drugs, please go to the February 8, 2008 FDA article FDA Notifies Public of Adverse Reactions Linked to Botox Use.